Rivermark Medical, Inc., a company focused on minimally invasive device therapy for benign prostatic hyperplasia (BPH), has secured a significant capital injection. The firm announced it has closed a $20.0M Series D funding round.
This latest investment, led by Andera Partners, will further support Rivermark Medical's ongoing development and advancement of its specialized device solutions for BPH treatment.

.png&w=3840&q=75)












.png&w=3840&q=75)
